Chinese CRO industry is setting off – the continued pandemic may bring the most potential to this industry.
The biotech lab tests are in great demand. Image credit_thisisengineering/Unsplash
Tigermed (300347:SH), the Chinese tier-one contract research organization just published its semi-annual financial report, disclosing revenue of CNY 1,452 million and net profits of CNY 1,012 million, 9.3% and 98% higher respectively.
With 17 overseas operational sites and offices, the company has carried out over 100 overseas clinical research projects. Its technology services for clinical research contributed CNY 710 million and laboratory research services CNY 740 million.
The company's major competitor WuXi AppTec (603259.SH;2359.HK), the tier-one CRO in China, reached a total revenue of CNY 7,231 million and profits of CNY 1,717 million, at 22.7% and 62.5% respectively. Not only these two benchmark companies have performed well, the whole biotechnology-based CRO industry in China is on the up wind.
The First Move of the U.S. Postal Service on Cross-Border E-commerce After Trump
Feb 21, 2025 08:19 PM
Shanghai and Shenzhen: The Dual-City Landscape and Corporate Power
Jan 09, 2025 03:35 PM